{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:23:24Z","timestamp":1774293804000,"version":"3.50.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Teduglutide, the first glucagon-like peptide 2 analogue, has been demonstrated to facilitate the absorption of gut nutrient and lessen the need for parenteral assistance in patients with Short Bowel Syndrome (SBS). However, its adverse drug events (AEs) are primarily documented in clinical trials, with a deficit in real-world data. This study evaluates the AEs profile of teduglutide based on Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>A disproportionality analysis of FAERS data from Quarter 1 (Q1) 2013 to Quarter 3 (Q3) 2023 was conducted to examine the association between teduglutide and adverse events, employing Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of 13,809,302 reports in the FAERS database, 10,114 reports identified teduglutide as the \u201cprimary suspect\u201d in AEs identification. During the dosing observation period, the median occurrence of adverse events was 393 days (interquartile range [IQR] 97\u2013996 days). Teduglutide-associated AEs occurred in 27 System Organ Classes (SOC), of which renal and urinary disorders is not mentioned in the specification. Based on the four algorithms, a total of 260 major disproportionality preferred terms (PTs) were filtered out, including previously unreported AEs including weight decreased (n = 805), vascular device infection (n = 683), dehydration (n = 596) and nephrolithiasis (n = 146).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our findings corroborate the AEs listed in the teduglutide prescribing information and additionally unveil new adverse reaction signals such as nephrolithiasis. These discoveries could aid in clinical monitoring and risk identification for teduglutide.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1404658","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T05:24:08Z","timestamp":1726118648000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaogan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangshuang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingbo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"G1038","DOI":"10.1152\/ajpgi.00282.2010","article-title":"Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon","volume":"299","author":"Amato","year":"2010","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jviscsurg.2017.12.012","article-title":"Medical and surgical management of short bowel syndrome","volume":"155","author":"Billiauws","year":"2018","journal-title":"J. Visc. Surg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.clnu.2017.10.002","article-title":"Assessing the impact of quality improvement measures on catheter related blood stream infections and catheter salvage: experience from a national intestinal failure unit","volume":"37","author":"Bond","year":"2018","journal-title":"Clin. Nutr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0167-0115(02)00095-2","article-title":"GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat","volume":"107","author":"Bozkurt","year":"2002","journal-title":"Regul. Pept."},{"key":"B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.regpep.2011.03.003","article-title":"The effect of Glucagon-Like Peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients","volume":"168","author":"Bremholm","year":"2011","journal-title":"Regul. Pept."},{"key":"B7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.clnesp.2018.07.006","article-title":"The impact of home parenteral nutrition on the burden of disease including morbidity, mortality and rate of hospitalisations","volume":"28","author":"Burden","year":"2018","journal-title":"Clin. Nutr. ESPEN"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2147\/tcrm.S166081","article-title":"Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome","volume":"14","author":"Chen","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"B9","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1097\/01.tp.0000757480.19792.d7","article-title":"O-03: a monocentric single-arm study on long-term safety and efficacy of teduglutide in SBS pediatric patients on long-term home-parenteral nutrition","volume":"105","author":"C","year":"2021","journal-title":"Transplantation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/mog.0000000000000631","article-title":"Advances in chronic intestinal failure management and therapies","volume":"36","author":"Deutsch","year":"2020","journal-title":"Curr. Opin. Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/0148607114549999","article-title":"Central venous catheter salvage in home parenteral nutrition catheter-related bloodstream infections: long-term safety and efficacy data","volume":"40","author":"Dibb","year":"2016","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clnu.2012.08.004","article-title":"Epidemiology of catheter-related infections in adult patients receiving home parenteral nutrition: a systematic review","volume":"32","author":"Dreesen","year":"2013","journal-title":"Clin. Nutr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4217","DOI":"10.1172\/JCI97233","article-title":"Discovery, characterization, and clinical development of the glucagon-like peptides","volume":"127","author":"Drucker","year":"2017","journal-title":"J. Clin. Investigation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nbt0797-673","article-title":"Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV","volume":"15","author":"Drucker","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1210\/en.2007-0561","article-title":"Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I","volume":"149","author":"Dub\u00e9","year":"2008","journal-title":"Endocrinology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am. Statistician"},{"key":"B18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/s0016-5085(03)00667-x","article-title":"GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1","volume":"125","author":"Guan","year":"2003","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/jpen.2061","article-title":"Safety findings in pediatric patients during long-term treatment with teduglutide for short-bowel syndrome-associated intestinal failure: pooled analysis of 4 clinical studies","volume":"45","author":"Hill","year":"2021","journal-title":"J. Parenter. Enter. Nutr. Sep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.regpep.2012.10.002","article-title":"Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients","volume":"180","author":"Hoyerup","year":"2013","journal-title":"Regul. Pept."},{"key":"B22","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1159\/000527502","article-title":"Glucagon-like peptide-2 ameliorates age-associated bone loss and gut barrier dysfunction in senescence-accelerated mouse prone 6 mice","volume":"69","author":"Huang","year":"2023","journal-title":"Gerontology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1136\/gut.2010.218271","article-title":"Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and\/or intravenous fluid requirements in patients with short bowel syndrome","volume":"60","author":"Jeppesen","year":"2011","journal-title":"Gut"},{"key":"B24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1053\/gast.2001.22555","article-title":"Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon","volume":"120","author":"Jeppesen","year":"2001","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.clnu.2013.03.016","article-title":"Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide - analyses from a randomised, placebo-controlled study","volume":"32","author":"Jeppesen","year":"2013","journal-title":"Clin. Nutr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1053\/j.gastro.2012.09.007","article-title":"Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure","volume":"143","author":"Jeppesen","year":"","journal-title":"Gastroenterology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/jpen.1690","article-title":"Safety and efficacy of teduglutide in pediatric patients with intestinal failure due to short bowel syndrome: a 24-week, phase III study","volume":"44","author":"Kocoshis","year":"2020","journal-title":"J. Parenter. Enter. Nutr. May"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ajcnut.2023.02.019","article-title":"Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome","volume":"117","author":"Lambe","year":"2023","journal-title":"Am. J. Clin. Nutr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.kint.2016.05.027","article-title":"Calcium and vitamin D have a synergistic role in a rat model of kidney stone disease","volume":"90","author":"Letavernier","year":"2016","journal-title":"Kidney Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1172\/JCI116246","article-title":"Increased intestinal vitamin D receptor in genetic hypercalciuric rats. A cause of intestinal calcium hyperabsorption","volume":"91","author":"Li","year":"1993","journal-title":"J. Clin. Investigation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/jpen.2221","article-title":"Characterization of American teduglutide consumers from 2015 to 2020: a large database study","volume":"46","author":"Loutfy","year":"2022","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"B32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/0091270009342252","article-title":"Population pharmacokinetics of teduglutide following repeated subcutaneous administrations in healthy participants and in patients with short bowel syndrome and Crohn's disease","volume":"50","author":"Marier","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.3748\/wjg.v12.i26.4117","article-title":"Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation","volume":"12","author":"Martin","year":"2006","journal-title":"World J. Gastroenterology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00228-012-1455-7","article-title":"Pharmacokinetics of teduglutide in subjects with renal impairment","volume":"69","author":"Nave","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1136\/gut.33.11.1493","article-title":"Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel","volume":"33","author":"Nightingale","year":"1992","journal-title":"Gut"},{"key":"B36","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.cgh.2012.12.029","article-title":"Safety and efficacy of teduglutide after 52 Weeks of treatment in patients with short bowel intestinal failure","volume":"11","author":"O'Keefe","year":"","journal-title":"Clin. Gastroenterology Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1756284820905766","DOI":"10.1177\/1756284820905766","article-title":"Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials","volume":"13","author":"Pape","year":"2020","journal-title":"Ther. Adv. Gastroenterology. Apr"},{"key":"B38","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/jpen.1593","article-title":"A single urine sodium measurement may validly estimate 24-hour urine sodium excretion in patients with an ileostomy","volume":"44","author":"Pedersen","year":"2020","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"B39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clnu.2016.01.020","article-title":"ESPEN guidelines on chronic intestinal failure in adults","volume":"35","author":"Pironi","year":"2016","journal-title":"Clin. Nutr."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6258","DOI":"10.3748\/wjg.v28.i44.6258","article-title":"Glucagon-like peptide-2 analogues for Crohn's disease patients with short bowel syndrome and intestinal failure","volume":"28","author":"Pizzoferrato","year":"2022","journal-title":"World J. Gastroenterology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1038\/ctg.2015.69","article-title":"Long-term teduglutide for the treatment of patients with intestinal failure associated with short bowel syndrome","volume":"7","author":"Schwartz","year":"2016","journal-title":"Clin. Transl. Gastroenterology. Feb"},{"key":"B43","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.cmet.2013.06.014","article-title":"Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons","volume":"18","author":"Shi","year":"2013","journal-title":"Cell Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1002\/jpen.2051","article-title":"Short-bowel syndrome: epidemiology, hospitalization trends, in-hospital mortality, and healthcare utilization","volume":"45","author":"Siddiqui","year":"2021","journal-title":"JPEN J. Parenter. Enter. Nutr."},{"key":"B45","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/77535","article-title":"The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake","volume":"6","author":"Tang-Christensen","year":"2000","journal-title":"Nat. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/ajcn\/nqy010","article-title":"Catheter-related bloodstream infections in patients with intestinal failure receiving home parenteral support: risks related to a catheter-salvage strategy","volume":"107","author":"Tribler","year":"2018","journal-title":"Am. J. Clin. Nutr."},{"key":"B47","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2147\/ceg.S42665","article-title":"Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block","volume":"7","author":"Vipperla","year":"2014","journal-title":"Clin. Exp. gastroenterology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1404658\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T05:24:11Z","timestamp":1726118651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1404658\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1404658"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1404658","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"article-number":"1404658"}}